Cost-effectiveness of pregabalin versus venlafaxine in the treatment of generalized anxiety disorder: Findings from a Spanish perspective

20Citations
Citations of this article
56Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The objective of the present study was to describe a new model of the cost-effectiveness of treatment of generalized anxiety disorder (GAD) and its application to a comparison of pregabalin versus venlafaxine extended-release (XR) from a Spanish healthcare perspective. Microsimulation techniques, including Hamilton Anxiety Scale (HAM-A) score, number of weeks with minimal or no anxiety (HAM-A 9), and quality-adjusted life-years (QALYs), were used to predict treatment outcomes for patients with moderate-to-severe GAD who would be treated with pregabalin vs venlafaxine XR. Expected levels of healthcare utilization and unit cost of care are derived from Spanish published sources. We express cost-effectiveness alternatively in terms of incremental cost per additional week with minimal or no anxiety, and incremental cost per QALY gained [in 2007 Euros (€)]. Considering costs of drug treatment only, the incremental cost [mean (95% confidence interval)] of pregabalin (vs venlafaxine XR) would be €96 (€86, €107) per additional week with minimal or no anxiety, and €32,832 (€29,656, €36,308) per QALY gained. When other medical care costs are considered, cost-effectiveness ratios decline to €70 (€61, €80) per additional week with no or minimal anxiety, and €23,909 (€20,820, €27,006) per QALY gained. We conclude that, using a new microsimulation model of the treatment of GAD, pregabalin appears to be cost-effective vs venlafaxine XR in a Spanish healthcare setting.

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Vera-Llonch, M., Dukes, E., Rejas, J., Sofrygin, O., Mychaskiw, M., & Oster, G. (2010). Cost-effectiveness of pregabalin versus venlafaxine in the treatment of generalized anxiety disorder: Findings from a Spanish perspective. European Journal of Health Economics, 11(1), 35–44. https://doi.org/10.1007/s10198-009-0160-7

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 23

62%

Researcher 8

22%

Professor / Associate Prof. 4

11%

Lecturer / Post doc 2

5%

Readers' Discipline

Tooltip

Medicine and Dentistry 15

45%

Economics, Econometrics and Finance 7

21%

Psychology 6

18%

Pharmacology, Toxicology and Pharmaceut... 5

15%

Save time finding and organizing research with Mendeley

Sign up for free